Evidence mapPaperPMID 40428368Full record

Observational studyGenes2025

Association of

Astrid Lorena Urbano-Cano, Rosa Elvira Álvarez-Rosero, Yamil Liscano

Abstract readObservational Study
In one paragraph

Observational study in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Atherogenic Dyslipidemia and Its Association withInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Astrid Lorena Urbano-CanoGrupo de Investigación en Salud Integral (GISI), Departamento Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia.ORCID 0000-0001-9902-9185
Rosa Elvira Álvarez-RoseroGrupo de Investigación en Genética Humana Aplicada (GIGHA), Departamento de Ciencias Fisiológicas, Universidad del Cauca, Popayan 190003, Colombia.ORCID 0000-0001-6507-5984
Yamil LiscanoGrupo de Investigación en Salud Integral (GISI), Departamento Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia.ORCID 0000-0002-2674-8725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease remains the leading cause of death worldwide, and dyslipidemia is a critical, modifiable risk factor.

aimWe sought to evaluate the relationship between polymorphisms in

methodsIn this cross-sectional observational study, 304 participants aged 40-69 years were enrolled. Clinical, anthropometric, and biochemical data were collected, and genotyping was performed for the four target polymorphisms. We used descriptive statistics to characterize the sample, non-parametric tests to compare lipid levels by genotype, and multivariable logistic regression to identify independent predictors of dyslipidemia.

resultsIndividuals with dyslipidemia exhibited significantly higher total cholesterol and VLDL levels, lower HDL levels, and an elevated Castelli II index compared with the non-dyslipidemia group. Although

conclusionsOur findings underscore the interplay between metabolic factors and genetic variants in the pathogenesis of dyslipidemia. Notably, the

Indexed as

Apolipoprotein A-VAryldialkylphosphataseCardiovascular DiseasesCholesterol Ester Transfer ProteinsDyslipidemiasInterleukin-6AdultAgedColombiaCross-Sectional StudiesFemaleGenetic Predisposition to DiseaseGenotypeHeart Disease Risk FactorsHumansMaleAPOA5 protein, humanApolipoprotein A-VAryldialkylphosphataseCETP protein, humanCholesterol Ester Transfer ProteinsIL6 protein, humanInterleukin-6PON1 protein, humanAPOA5cardiovascular riskCETPgenetic polymorphismsIL6PON1

Identifiers

PMID40428368
PMCPMC12111601

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.